P300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 5, 2013, Pages 1028-1040

  Kaur, Jasmine ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

EGFR; Gefitinib; Histone; P300 CBP; T790M

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HISTONE; HISTONE ACETYLTRANSFERASE; NANOPARTICLE; POLYGLACTIN; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CARCINOMA CELL; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYDRODYNAMICS; LUNG CARCINOMA; NANOENCAPSULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; WILD TYPE; ZETA POTENTIAL;

EID: 84874366062     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.01.029     Document Type: Article

References (52)

1. Thomas S.M., Grandis J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev. 2004, 30:255-268.
2. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., Tada H., Kuwano H., Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with nonâ€"small cell lung cancer and acquired resistance to gefitinib". Clin. Cancer Res. 2006, 12:5764-5769.
3. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 2006, 12:6494-6501.
4. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:225-235.
5. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. 2008, 105:2070-2075.
6. Wang A.Z., Gu F., Zhang L., Chan J.M., Radovic-Moreno A., Shaikh M.R., Farokhzad O.C. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 2008, 8:1063-1070.
7. Hu C.M.J., Kaushal S., Cao H.S.T., Aryal S., Sartor M., Esener S., Bouvet M., Zhang L. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol. Pharm. 2010, 7:914-920.
8. Hu C.M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
9. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 2006, 317:1372-1381.
10. Gu Y.J., Cheng J., Man C.W.Y., Wong W.T., Cheng S.H. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 2012, 8:204-211.
11. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., Zhang L., Lu W.L. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
12. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., Nel A.E. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
13. Misra R., Sahoo S.K. Co-formulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppress the development of multi drug resistance in K562 cells. Mol. Pharm. 2011, 8:852-866.
14. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012, 7:779-786.
15. Boury F., Ivanova T., PanaıÌ̂otov I., Proust J.E., Bois A., Richou J. Dynamic properties of poly (DL-lactide) and polyvinyl alcohol monolayers at the air/water and dichloromethane/water interfaces. J. Colloid Interface Sci. 1995, 169:380-392.
16. Wischke C., Schwendeman S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 2008, 364:298-327.
17. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., Kumar M.N.V. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J. Control. Release 2007, 119:197-206.
18. Sonaje K., Italia J.L., Sharma G., Bhardwaj V., Tikoo K., Kumar M.N.V.R. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm. Res. 2007, 24:899-908.
19. Tikoo K., Bhatt D.K., Gaikwad A.B., Sharma V., Kabra D.G. Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Lett. 2007, 581:2027-2035.
20. Bodmeier R., McGinity J.W. Solvent selection in the preparation of poly (DL-lactide) microspheres prepared by the solvent evaporation method. Int. J. Pharm. 1988, 43:179-186.
21. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30:5737-5750.
22. Tzafriri A.R., Lerner E.I., Flashner-Barak M., Hinchcliffe M., Ratner E., Parnas H. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres. Clin. Cancer Res. 2005, 11:826-834.
23. Vekariya K.K., Kaur J., Tikoo K. ER-α signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer. Nanomedicine 2012, 8:1125-1132.
24. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004, 3:465-472.
25. Noro R., Gemma A., Kosaihira S., Kokubo Y., Chen M., Seike M., Kataoka K., Matsuda K., Okano T., Minegishi Y. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006, 6:277-289.
26. Suenaga M., Yamaguchi A., Soda H., Orihara K., Tokito Y., Sakaki Y., Umehara M., Terashi K., Kawamata N., Oka M. Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006, 26:3387-3391.
27. Kobayashi S., Boggon T.J., Dayaram T., JÃnne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
28. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
29. MailaÌ̂nder V., Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10:2379-2400.
30. dos Santos T., Varela J., Lynch I., Salvati A., Dawson K.A. Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small 2011, 7:3341-3349.
31. Kim J.A., Aberg C., Salvati A., Dawson K.A. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 2012, 7:62-68.
32. Davda J., Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 2002, 233:51-59.
33. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3:802-808.
34. Rakowicz-Szulczynska E.M., Rodeck U., Herlyn M., Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc. Natl. Acad. Sci. 1986, 83:3728-3732.
35. Balch C., Huang T.H.M., Brown R., Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 2004, 191:1552-1572.
36. Glasspool R.M., Teodoridis J.M., Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 2006, 94:1087-1092.
37. O'Byrne K.J., Barr M.P., Gray S.G. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancer 2011, 3:1426-1453.
38. Xiong H., Du W., Zhang Y.J., Hong J., Su W.Y., Tang J.T., Wang Y.C., Lu R., Fang J.Y. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol. Carcinog. 2012, 51:174-184.
39. Peck B., Chen C.Y., Ho K.K., Di Fruscia P., Myatt S.S., Coombes R.C., Fuchter M.J., Hsiao C.D., Lam E.W.F. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 2010, 9:844-855.
40. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 2001, 268:2773-2778.
41. Zhou W., Zhu W.G. The changing face of HDAC inhibitor depsipeptide. Curr. Cancer Drug Targets 2009, 9:91-100.
42. Rosato R.R., Almenara J.A., Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003, 63:3637-3645.
43. Liu G., Xia T., Chen X. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J. Biol. Chem. 2003, 278:17557-17565.
44. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., Saijo N., Nishio K. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa®(ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int. J. Cancer 2002, 98:310-315.
45. Moon D.O., Kim M.O., Heo M.S., Lee J.D., Choi Y.H., Kim G.Y. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch. Pharm. Res. 2009, 32:1351-1360.
46. Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., Sun Y., Han X. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat. Rec. (Hoboken) 2009, 292:1122-1127.
47. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., Kundu T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279:33716-33726.
48. Wells A., Marti U. Signalling shortcuts: cell-surface receptors in the nucleus?. Nat. Rev. Mol. Cell Biol. 2002, 3:697-702.
49. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589.
50. Chiu H.C., Chou D.L., Huang C.T., Lin W.H., Lien T.W., Yen K.J., Hsu J.T.A. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem. Pharmacol. 2011, 81:1263-1270.
51. Yu Z., Zhang W., Kone B.C. Histone deacetylases augment cytokine induction of the iNOS gene. J. Am. Soc. Nephrol. 2002, 13:2009-2017.
52. Fabre C., Grosjean J., Tailler M., Boehrer S., AdÃr̈s L., Perfettini J.L., de Botton S., Fenaux P., Kroemer G. A novel effect of DNA methyltransferase and histone deacetylase inhibitors. Cell Cycle 2008, 7:2139-2145.